
  
    
      
        Introduction_NNP
        Autoreactive_NNP T_NN cells_NNS are_VBP primarily_RB eliminated_VBN in_IN the_DT
        thymus_JJ by_IN negative_JJ selection_NN (_( central_JJ tolerance_NN )_) ._. Some_DT of_IN
        the_DT autoreactive_JJ T_NN cells_NNS ,_, however_RB ,_, may_MD escape_VB from_IN negative_JJ
        selection_NN and_CC are_VBP released_VBN into_IN the_DT periphery_NN ._. These_DT
        self-reactive_JJ T_NN cells_NNS are_VBP exquisitely_RB regulated_VBN ,_, and_CC their_PRP$
        activation_NN can_MD result_VB in_IN autoimmune_JJ diseases_NNS ._. There_EX is_VBZ
        accumulating_VBG evidence_NN that_IN ,_, in_IN addition_NN to_TO
        activation-induced_JJ cell_NN death_NN or_CC anergy_NN ,_, T-_NNP cell-mediated_JJ
        dominant_JJ control_NN of_IN self-reactive_JJ T_NN cells_NNS represents_VBZ one_CD
        mechanism_NN for_IN maintaining_VBG immunological_JJ tolerance_NN [_NN 1_CD 2_CD 3_CD ]_NN
        ._. Studies_NNPS conducted_VBD in_IN a_DT number_NN of_IN experimental_JJ models_NNS have_VBP
        demonstrated_VBN the_DT existence_NN of_IN regulatory_JJ T-_NNP cell_NN subsets_NNS
        that_WDT prevent_VBP activation_NN of_IN autoreactive_JJ T_NN cells_NNS ._. Recently_RB ,_,
        a_DT subset_NN of_IN CD_NNP 4_CD +_NN T_NN cells_NNS was_VBD identified_VBN that_WDT is_VBZ present_JJ on_IN
        5_CD -_: 10_CD %_NN of_IN CD_NNP 4_CD +_NN T_NN cells_NNS in_IN normal_JJ naïve_NN mice_NNS and_CC expresses_VBZ
        CD_NNP 25_CD (_( the_DT α-chain_JJ of_IN IL-_NNP 2_CD receptor_NN )_) [_NN 4_CD 5_CD ]_NN ._. Functional_NNP
        analysis_NN of_IN murine_NN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS showed_VBD that_IN those_DT
        cells_NNS ,_, which_WDT constitutively_RB express_VB cytotoxic_JJ T-_NNP lymphocyte_NN
        antigen_NN (_( CTLA_NNP )_) -_: 4_CD [_NN 6_CD 7_CD 8_CD ]_NN ,_, fail_VB to_TO proliferate_VBP or_CC secret_JJ
        cytokines_NNS in_IN response_NN to_TO polyclonal_NN or_CC antigen-specific_JJ
        stimulation_NN ,_, but_CC inhibit_VB the_DT activation_NN of_IN conventional_JJ
        responsive_JJ T_NN cells_NNS [_NN 1_CD 2_CD 3_CD 8_CD 9_CD ]_NN ._. The_DT suppressive_JJ activity_NN
        of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS depends_VBZ on_IN signaling_VBG via_IN the_DT
        negative_JJ regulator_NN of_IN T-_NNP cell_NN activation_NN CTLA-_NNP 4_CD [_NN 7_CD ]_NN and_CC
        requires_VBZ a_DT cell-cell_JJ interaction_NN that_WDT possibly_RB involves_VBZ
        cell_NN surface_NN bound_VBN transforming_VBG growth_NN factor_NN (_( TGF_NNP )_) -_: β_NN 
        1_CD [_NN 1_CD 10_CD ]_NN ._. It_PRP has_VBZ been_VBN shown_VBN that_IN
        B_NNP 7_CD /_NN CD_NNP 28_CD costimulation_NN is_VBZ essential_JJ for_IN the_DT development_NN and_CC
        homeostasis_NNS of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS [_NN 6_CD ]_NN ,_,
        which_WDT play_VBP critical_JJ roles_NNS not_RB only_RB in_IN preventing_VBG
        autoimmunity_NN but_CC also_RB in_IN controlling_VBG tumor_NN immunity_NN and_CC
        transplantation_NN tolerance_NN [_NN 2_CD 11_CD ]_NN ._.
        Proteoglycan-induced_NNP arthritis_NN (_( PGIA_NNP )_) is_VBZ a_DT novel_NN
        autoimmune_JJ murine_NN model_NN that_WDT is_VBZ induced_VBN by_IN systemic_JJ
        immunization_NN of_IN BALB_NNP /_NN c_SYM mice_NNS with_IN cartilage_NN proteoglycans_NNS [_NN
        12_CD 13_CD ]_NN ._. The_DT development_NN of_IN PGIA_NNP is_VBZ based_VBN on_IN the_DT
        cross-reactive_JJ immune_JJ response_NN between_IN immunizing_VBG human_NN and_CC
        mouse_NN (_( self_NN )_) cartilage_NN proteoglycans_NNS in_IN genetically_RB
        susceptible_JJ BALB_NNP /_NN c_SYM mice_NNS [_NN 12_CD 13_CD ]_NN ._. Several_JJ lines_NNS of_IN
        evidence_NN indicate_VBP T-_NNP cell_NN involvement_NN in_IN the_DT pathogenesis_NNS of_IN
        PGIA_NNP ._. First_LS ,_, CD_NNP 4_CD +_NN T_NN cells_NNS selectively_RB proliferate_VBP in_IN
        response_NN to_TO proteoglycan_NN antigens_NNS [_NN 14_CD ]_NN ._. Second_JJ ,_,
        prevention_NN of_IN arthritis_NN can_MD be_VB achieved_VBN by_IN 
        in_IN vivo_NN treatment_NN with_IN anti-_NN CD_NNP 4_CD
        monoclonal_NN antibodies_NNS [_NN 15_CD ]_NN ._. Third_NNP ,_, arthritis_NN can_MD be_VB
        transferred_VBN to_TO naïve_NN BALB_NNP /_NN c_SYM or_CC severe_JJ combined_VBN
        immunodeficient_NN (_( SCID_NNP )_) mice_NNS using_VBG T_NN and_CC B_NNP cells_NNS from_IN
        arthritic_JJ animals_NNS [_NN 16_CD 17_CD 18_CD ]_NN ._. Fourth_JJ ,_, a_DT
        proteoglycan-specific_JJ T-_NNP cell_NN hybridoma_NN (_( T-_NNP helper-_NN 1_CD type_NN )_)
        can_MD induce_VB arthritis_NN in_IN BALB_NNP /_NN c_SYM mice_NNS [_NN 19_CD ]_NN ._. Finally_RB ,_, CD_NNP 4_CD
        +_NN T_NN cells_NNS from_IN arthritic_JJ animals_NNS are_VBP resistant_JJ to_TO
        activation-induced_JJ cell_NN death_NN [_NN 20_CD ]_NN ._. These_DT data_NNS suggest_VBP a_DT
        breakdown_NN of_IN peripheral_JJ tolerance_NN and_CC accumulation_NN of_IN
        autoreactive_JJ T_NN cells_NNS in_IN the_DT periphery_NN ._.
        In_IN order_NN to_TO determine_VB whether_IN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN
        cells_NNS play_VBP a_DT role_NN in_IN the_DT development_NN of_IN PGIA_NNP ,_, we_PRP monitored_VBD
        the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN -_: expressing_VBG regulatory_JJ T_NN cells_NNS in_IN mice_NNS with_IN
        PGIA_NNP during_IN an_DT entire_JJ immunization_NN period_NN ._. We_PRP also_RB
        transferred_VBD purified_JJ CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS from_IN naïve_NN BALB_NNP /_NN c_SYM
        mice_NNS together_RB with_IN spleen_NN cells_NNS from_IN arthritic_JJ animals_NNS ,_, or_CC
        alternatively_RB transferred_VBN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN -_: depleted_VBN spleen_NN cells_NNS
        from_IN arthritic_JJ animals_NNS into_IN SCID_NNP mice_NNS ,_, and_CC then_RB monitored_VBN
        disease_NN development_NN in_IN SCID_NNP mice_NNS ._. In_IN addition_NN ,_, we_PRP examined_VBD
        disease_NN incidence_NN in_IN CD_NNP 28_CD -_: deficient_NN mice_NNS ,_, which_WDT have_VBP
        deficiency_NN in_IN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS ._. Our_PRP$ data_NNS suggest_VBP that_IN the_DT
        CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS might_MD not_RB be_VB essential_JJ for_IN
        controlling_VBG the_DT development_NN of_IN PGIA_NNP ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Antigen_NNP ,_, mice_NNS and_CC immunization_NN
          High-density_NNP cartilage_NN proteoglycan_NN (_( aggrecan_NN )_) was_VBD
          purified_JJ from_IN human_JJ cartilage_NN ,_, by_IN CsCl_NNP gradient_NN
          centrifugation_NN ,_, and_CC depleted_VBD of_IN glycosaminoglycan_NN side_NN
          chains_NNS as_IN described_VBN previously_RB [_NN 21_CD ]_NN ._. Female_NNP BALB_NNP /_NN c_SYM
          mice_NNS (_( National_NNP Cancer_NNP Institute_NNP ,_, Friedrich_NNP ,_, MD_NNP ,_, USA_NNP ,_, or_CC
          The_DT Jackson_NNP Laboratory_NNP ,_, Bar_NNP Harbor_NNP ,_, ME_NNP ,_, USA_NNP )_) and_CC
          CD_NNP 28_CD -_: deficient_NN mice_NNS (_( The_DT Jackson_NNP Laboratory_NNP )_) were_VBD
          immunized_JJ intraperitoneally_RB with_IN cartilage_NN proteoglycan_NN
          (_( 100_CD μg_NN protein_NN )_) in_IN complete_JJ Freund_NNP 's_POS adjuvant_NN on_IN day_NN 0_CD ,_,
          and_CC boosted_VBD with_IN proteoglycan_NN in_IN incomplete_JJ Freund_NNP 's_POS
          adjuvant_NN on_IN days_NNS 21_CD and_CC 42_CD ._. Female_NNP SCID_NNP mice_NNS on_IN a_DT BALB_NNP /_NN c_SYM
          background_NN (_( NCI_NNP /_NN NCrC_NNP ._. B-_NNP 17_CD -_: scid_NN /_NN scid_NN )_) ,_, aged_VBN 8_CD -_: 12_CD weeks_NNS or_CC
          young_JJ retired_VBD breeders_NNS ,_, were_VBD purchased_VBN from_IN the_DT National_NNP
          Cancer_NNP Institute_NNP and_CC maintained_VBN under_IN germ-free_JJ
          conditions_NNS ._.
        
        
          Assessment_NNP of_IN arthritis_NN
          A_DT standard_JJ scoring_VBG system_NN ,_, based_VBN on_IN swelling_VBG and_CC
          redness_NNS of_IN each_DT paw_NN ,_, was_VBD used_VBN for_IN the_DT assessment_NN of_IN the_DT
          severity_NN of_IN disease_NN ._. The_DT first_JJ clinical_JJ symptom_NN of_IN
          swelling_VBG was_VBD recorded_VBN as_IN the_DT time_NN of_IN onset_NN of_IN arthritis_NN ._.
          Joint_NNP swelling_VBG was_VBD scored_VBN (_( ranging_VBG from_IN 0_CD to_TO 4_CD in_IN each_DT
          paw_NN )_) and_CC expressed_VBD as_IN acute_JJ cumulative_JJ arthritis_NN score_NN ,_,
          resulting_VBG in_IN a_DT possible_JJ maximum_NN severity_NN score_NN of_IN 16_CD ._.
          Typically_RB ,_, in_IN the_DT primary_JJ form_NN of_IN PGIA_NNP ,_, BALB_NNP /_NN c_SYM mice_NNS
          developed_VBD swelling_VBG and_CC redness_NNS in_IN one_CD or_CC more_JJR limbs_NNS 7_CD -_: 14_CD
          days_NNS after_IN the_DT third_JJ injection_NN with_IN proteoglycan_NN and_CC
          adjuvant_NN ._. In_IN the_DT transfer_NN system_NN ,_, recipient_JJ SCID_NNP mice_NNS
          developed_VBD a_DT more_JJR uniform_NN disease_NN from_IN day_NN 10_CD after_IN
          transfer_NN ,_, with_IN involvement_NN of_IN nearly_RB all_DT peripheral_JJ
          joints_NNS ._.
        
        
          Flow_NNP cytometry_NN analysis_NN
          The_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN -_: expressing_VBG T_NN cells_NNS were_VBD identified_VBN by_IN
          staining_VBG spleen_NN cells_NNS with_IN fluorescein_NN isothiocyanate_NN
          (_( FITC_NNP )_) -_: labeled_VBN anti-_NN CD_NNP 4_CD and_CC biotin-labeled_JJ anti-_NN CD_NNP 25_CD
          followed_VBN by_IN CyChrome-labeled_NNP streptavidin_NN (_( BD_NNP PharMingen_NNP ,_,
          San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, and_CC analyzed_VBD on_IN a_DT flow_NN cytometer_NN
          (_( Beckton_NNP Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. For_IN analysis_NN of_IN
          intracellular_NN CTLA-_NNP 4_CD ,_, spleen_NN cells_NNS were_VBD first_JJ stained_JJ
          with_IN the_DT above_JJ fluorescence-labeled_JJ antibodies_NNS ,_, fixed_VBN and_CC
          rendered_VBN permeable_JJ ,_, and_CC stained_JJ with_IN R-_NNP phycoerythrin_NN
          (_( PE_NNP )_) -_: labeled_VBN anti-_NN CTLA-_NNP 4_CD using_VBG a_DT Cytofix_NNP /_NN Cytoperm_NNP kit_NN (_( BD_NNP
          PharMingen_NNP )_) ._.
        
        
          Purification_NNP of_IN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN and_CC CD_NNP 4_CD +_NN CD_NNP 25_CD -_: T_NN cells_NNS
          and_CC cell_NN transfer_NN in_IN SCID_NNP mice_NNS
          The_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS were_VBD purified_JJ using_VBG a_DT protocol_NN
          described_VBD previously_RB [_NN 6_CD ]_NN ._. Briefly_NNP ,_, CD_NNP 4_CD +_NN T_NN cells_NNS were_VBD
          isolated_VBN from_IN spleens_NNS of_IN 10_CD -_: to_TO 12_CD -_: week-old_JJ ,_, naïve_NN ,_,
          BALB_NNP /_NN c_SYM mice_NNS by_IN negative_JJ selection_NN using_VBG CD_NNP 4_CD -_: enrichment_NN
          columns_NNS (_( R_NN &_CC D_NNP System_NNP ,_, Minneapolis_NNP ,_, MN_NNP ,_, USA_NNP )_) ._. Purified_NNP
          CD_NNP 4_CD +_NN T_NN cells_NNS were_VBD incubated_JJ with_IN PE-labeled_NNP anti-_NN CD_NNP 25_CD ,_,
          and_CC the_DT stained_JJ cells_NNS were_VBD incubated_JJ with_IN anti-_NN PE_NNP
          microbeads_NNS (_( Miltenyi_NNP Biotech_NNP Inc_NNP ._. ,_, Auburn_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. The_DT
          CD_NNP 25_CD +_NN cells_NNS were_VBD selected_VBN on_IN an_DT LS_NNP +_NN column_NN (_( Miltenyi_NNP
          Biotech_NNP Inc_NNP ._. )_) ._. The_DT purity_NN of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS was_VBD
          approximately_RB 90_CD %_NN ._. The_DT CD_NNP 4_CD +_NN CD_NNP 25_CD -_: T_NN cells_NNS ,_, which_WDT did_VBD not_RB
          bind_NN to_TO magnetic_JJ beads_NNS ,_, were_VBD collected_VBN from_IN the_DT flow_NN
          through_IN the_DT washing_VBG steps_NNS (_( purity_NN >_NN 98_CD %_NN )_) ._. A_DT total_NN of_IN 5_CD
          ×_NN 10_CD 5_CD CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN or_CC CD_NNP 4_CD +_NN CD_NNP 25_CD -_: T_NN cells_NNS were_VBD injected_VBN
          intraperitoneally_RB ,_, along_IN with_IN 1_CD ×_NN 10_CD 7_CD spleen_NN cells_NNS from_IN
          arthritic_JJ animals_NNS that_WDT were_VBD depleted_VBN of_IN CD_NNP 25_CD +_NN cells_NNS and_CC
          100_CD μg_NN proteoglycan_NN ,_, into_IN SCID_NNP mice_NNS ._.
        
        
          Depletion_NNP of_IN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS and_CC cell_NN
          transfer_NN
          Spleen_NNP cells_NNS from_IN arthritic_JJ animals_NNS were_VBD depleted_VBN of_IN
          CD_NNP 25_CD +_NN cells_NNS using_VBG negative_JJ selection_NN as_IN described_VBN above_IN
          (_( 0_CD ._. 5_LS μg_NN PE-labeled_NNP anti-_NN CD_NNP 25_CD per_IN 1_CD ×_NN 10_CD 6_CD cells_NNS )_) ._. The_DT
          depletion_NN of_IN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN cells_NNS was_VBD detected_VBN by_IN flow_NN
          cytometry_NN ._. Typically_RB ,_, less_JJR than_IN 0_CD ._. 3_CD %_NN of_IN the_DT depleted_VBN
          cells_NNS expressed_VBD CD_NNP 25_CD ._. a_DT total_NN of_IN 1_CD ×_NN 10_CD 7_CD CD_NNP 25_CD +_NN and_CC CD_NNP 25_CD
          -_: spleen_NN cells_NNS ,_, together_RB with_IN 100_CD μg_NN proteoglycan_NN ,_, were_VBD
          injected_VBN intraperitoneally_RB into_IN SCID_NNP mice_NNS ._.
        
        
          In_IN vitro_NN suppression_NN assay_NN
          CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS (_( 1_CD ×_NN 10_CD 4_LS )_) isolated_VBN from_IN naïve_NN
          BALB_NNP /_NN c_SYM mice_NNS were_VBD mixed_VBN with_IN CD_NNP 4_CD +_NN CD_NNP 25_CD -_: T_NN cells_NNS (_( 5_CD ×_NN 10_CD 4_LS )_)
          from_IN arthritic_JJ mice_NNS in_IN the_DT presence_NN of_IN irradiated_JJ
          syngenic_JJ splenocytes_NNS as_IN antigen-presenting_JJ cells_NNS (_( 7_CD ._. 5_LS ×_NN
          10_CD 4_LS )_) with_IN 1_CD μg_NN /_NN ml_NN soluble_JJ anti-_NN CD_NNP 3_CD for_IN 3_CD days_NNS or_CC 50_CD
          μg_NN /_NN ml_NN proteoglycan_NN for_IN 5_CD days_NNS ,_, and_CC T-_NNP cell_NN proliferation_NN
          was_VBD determined_VBN by_IN [_NN 3_CD H_NNP ]_NN thymidine_NN incorporation_NN ._.
        
        
          Measurements_NNP of_IN antigen-specific_JJ T-_NNP cell_NN responses_NNS ,_,
          antibodies_NNS ,_, and_CC cytokine_NN production_NN
          Antigen-specific_NNP T-_NNP cell_NN responses_NNS were_VBD measured_VBN in_IN
          quadriplicate_NN samples_NNS of_IN spleen_NN cells_NNS (_( 3_CD ×_NN 10_CD
          5_CD cells_NNS /_NN well_RB )_) cultured_JJ in_IN the_DT presence_NN of_IN 50_CD μg_NN
          proteoglycan_NN protein_NN /_NN ml_NN ._. T-_NNP cell_NN proliferation_NN was_VBD
          assessed_VBN on_IN day_NN 5_CD by_IN [_NN 3_CD H_NNP ]_NN thymidine_NN incorporation_NN [_NN 14_CD 22_CD
          ]_NN ._. Antigen_NNP (_( proteoglycan_NN )_) -_: specific_JJ interferon-γ_JJ ,_, IL-_NNP 10_CD ,_,
          and_CC IL-_NNP 4_CD production_NN by_IN T_NN cells_NNS was_VBD determined_VBN in_IN media_NNS
          collected_VBN on_IN day_NN 4_CD using_VBG capture_NN enzyme-linked_JJ
          immunosorbent_NN assays_NNS (_( ELISAs_NNP )_) from_IN BioSource_NNP
          International_NNP ,_, Inc_NNP ._. (_( Camarillo_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. For_IN induction_NN
          of_IN TGF-β_NNP 
          1_CD ,_, spleen_NN cells_NNS were_VBD cultured_JJ in_IN
          serum-free_JJ medium_NN X-V_NNP ivo-_NN 20_CD (_( BioWhittaker_NNP ,_, Inc_NNP ._. ,_,
          Walkersville_NNP ,_, MD_NNP ,_, USA_NNP )_) in_IN the_DT presence_NN of_IN proteoglycan_NN ._.
          Total_NNP TGF-β_NNP 
          1_CD was_VBD measured_VBN after_IN acidification_NN to_TO
          activate_VBP latent_NN TGF-β_NNP ,_, followed_VBN by_IN neutralization_NN using_VBG
          an_DT ELISA_NNP kit_NN from_IN Promega_NNP (_( Madison_NNP ,_, WI_NNP ,_, USA_NNP )_) ._.
          Maxisorp_NNP immunoplates_NNS (_( Nunc_NNP ,_, Rochester_NNP ,_, NY_NNP ,_, USA_NNP )_) were_VBD
          coated_VBN with_IN human_NN or_CC mouse_NN cartilage_NN proteoglycans_NNS (_( 0_CD ._. 1_LS
          μg_NN protein_NN /_NN 100_CD μl_NN per_IN well_RB )_) for_IN ELISA_NNP ,_, and_CC free_JJ binding_JJ
          capacity_NN of_IN the_DT wells_NNS was_VBD blocked_VBN by_IN 1_CD %_NN fat-free_JJ milk_NN in_IN
          phosphate-buffered_JJ saline_NN [_NN 23_CD 24_CD 25_CD ]_NN ._. Sera_NNP were_VBD
          applied_VBN at_IN increasing_VBG dilutions_NNS and_CC isotypes_NNS of_IN
          proteoglycan-specific_JJ antibodies_NNS were_VBD determined_VBN using_VBG
          peroxidase-conjugated_JJ rat_NN antimouse_NN IgG_NNP 
          1_CD or_CC IgG_NNP 
          2_CD a_DT secondary_JJ antibodies_NNS (_( Zymed_NNP ,_, South_NNP
          San_NNP Francisco_NNP ,_, CA_NNP ,_, USA_NNP )_) as_RB previously_RB described_VBD [_NN 24_CD 26_CD ]_NN
          ._. Serum_NNP antibody_NN levels_NNS were_VBD calculated_VBN according_VBG to_TO
          mouse_NN IgG_NNP 
          1_CD and_CC IgG_NNP 
          2_CD a_DT standards_NNS ._. Mouse_NNP IgG_NNP 
          1_CD and_CC IgG_NNP 
          2_CD a_DT standards_NNS were_VBD purified_JJ by_IN
          sepharose-coupled_JJ protein_NN G_NNP from_IN irrelevant_JJ
          (_( non-proteoglycan-specific_JJ )_) monoclonal_NN
          antibody-containing_JJ ascites_NNS fluids_NNS and_CC coated_JJ directly_RB
          onto_IN the_DT microplate_NN 's_POS surface_NN ._.
        
        
          Statistical_NNP analysis_NN
          Statistical_NNP analysis_NN was_VBD performed_VBN using_VBG SPSS_NNP v_NN 7_CD ._. 5_LS
          (_( SPSS_NNP ,_, Chicago_NNP ,_, IL_NNP ,_, USA_NNP )_) ._. The_DT Mann-_NNP Whitney_NNP and_CC Wilcoxon_NNP
          tests_NNS were_VBD used_VBN for_IN intergroup_NN comparisons_NNS ._. 
          P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          statistically_RB significant_JJ ._.
        
      
      
        Results_NNS
        
          Lack_NN of_IN correlation_NN between_IN development_NN of_IN
          arthritis_NN and_CC expression_NN of_IN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS
          in_IN PGIA_NNP
          To_TO elucidate_NN the_DT role_NN of_IN these_DT regulatory_JJ T_NN cells_NNS in_IN
          autoimmune_JJ arthritis_NN ,_, we_PRP first_RB followed_VBN up_RP the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD
          +_NN -_: expressing_VBG regulatory_JJ T_NN cells_NNS in_IN mice_NNS with_IN PGIA_NNP during_IN
          the_DT entire_JJ course_NN of_IN immunization_NN ._. To_TO exclude_VB the_DT
          possibility_NN that_IN different_JJ CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN -_: expressing_VBG T_NN cells_NNS
          may_MD be_VB a_DT strain-_NN and_CC /_NN or_CC antigen-dependent_JJ phenomenon_NN ,_, we_PRP
          immunized_JJ BALB_NNP /_NN c_SYM mice_NNS (_( PGIA-susceptible_NNP strain_NN )_) and_CC
          C_NNP 57_CD BL_NNP /_NN 6_CD (_( arthritis-resistant_JJ strain_NN )_) with_IN human_JJ cartilage_NN
          proteoglycan_NN or_CC ovalbumin_NN ._. As_IN shown_VBN in_IN Fig_NNP ._. 1_LS ,_, BALB_NNP /_NN c_SYM
          mice_NNS immunized_JJ with_IN human_JJ cartilage_NN proteoglycan_NN started_VBD
          to_TO develop_VB arthritis_NN after_IN the_DT third_JJ injection_NN and_CC the_DT
          incidence_NN of_IN arthritis_NN reached_VBD 100_CD %_NN at_IN day_NN 72_CD following_VBG
          the_DT third_JJ immunization_NN ,_, whereas_IN BALB_NNP /_NN c_SYM mice_NNS immunized_JJ
          with_IN ovalbumin_NN or_CC C_NNP 57_CD BL_NNP /_NN 6_CD mice_NNS immunized_JJ with_IN
          proteoglycan_NN were_VBD completely_RB resistant_JJ to_TO PGIA_NNP ._. The_DT CD_NNP 4_CD
          +_NN CD_NNP 25_CD +_NN -_: expressing_VBG T_NN cells_NNS detected_VBD 14_CD days_NNS after_IN each_DT
          immunization_NN from_IN each_DT experimental_JJ group_NN were_VBD similar_JJ
          during_IN the_DT entire_JJ course_NN of_IN immunization_NN (_( Fig_NNP ._. 2_LS a_DT )_) ._. This_DT
          observation_NN suggests_VBZ that_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN
          cells_NNS might_MD not_RB be_VB involved_VBN in_IN the_DT development_NN of_IN PGIA_NNP ._.
          Although_IN it_PRP has_VBZ been_VBN shown_VBN that_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ
          T_NN cells_NNS can_MD suppress_VB the_DT development_NN of_IN autoimmunity_NN ,_, a_DT
          recent_JJ report_NN [_NN 27_CD ]_NN demonstrated_VBN that_DT depletion_NN of_IN the_DT
          CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS is_VBZ necessary_JJ but_CC not_RB sufficient_JJ for_IN
          induction_NN of_IN autoimmune_JJ gastritis_NNS ._.
          It_PRP has_VBZ been_VBN shown_VBN that_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN
          cells_NNS express_VBP CTLA-_NNP 4_CD [_NN 6_CD 7_CD 8_CD ]_NN ,_, which_WDT is_VBZ a_DT negative_JJ
          regulator_NN of_IN T-_NNP cell_NN activation_NN ._. The_DT suppressive_JJ activity_NN
          of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS may_MD in_IN part_VB be_VB
          ascribed_VBN to_TO signaling_VBG through_IN CTLA-_NNP 4_CD ._. CTLA-_NNP 4_CD may_MD
          transduce_NN an_DT activating_VBG signal_NN to_TO CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN
          cells_NNS [_NN 2_CD ]_NN ._. Although_IN we_PRP did_VBD not_RB detect_VB any_DT significant_JJ
          decrease_NN in_IN numbers_NNS of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS
          between_IN proteoglycan-immunized_JJ BALB_NNP /_NN c_SYM and_CC C_NNP 57_CD BL_NNP /_NN 6_CD mice_NNS ,_,
          this_DT might_MD be_VB due_JJ to_TO reduced_VBN expression_NN of_IN CTLA-_NNP 4_CD in_IN the_DT
          CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS from_IN proteoglycan-immunized_JJ
          BALB_NNP /_NN c_SYM mice_NNS ._. To_TO test_VB this_DT possibility_NN ,_, we_PRP then_RB detected_VBD
          CTLA-_NNP 4_CD expression_NN on_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS
          using_VBG intracellular_NN staining_VBG ._. There_EX was_VBD no_DT significant_JJ
          difference_NN between_IN levels_NNS of_IN CTLA-_NNP 4_CD expression_NN in_IN the_DT CD_NNP 4_CD
          +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS from_IN each_DT group_NN (_( Fig_NNP ._. 2_LS b_SYM )_) ._. This_DT
          finding_VBG excludes_VBZ the_DT possibility_NN that_WDT reduced_VBD expression_NN
          of_IN CTLA-_NNP 4_CD in_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS from_IN
          BALB_NNP /_NN c_SYM mice_NNS with_IN PGIA_NNP may_MD mediate_VB the_DT induction_NN of_IN the_DT
          disease_NN ._.
        
        
          CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS may_MD not_RB control_VB
          autoimmune_JJ arthritis_NN
          To_TO further_VB investigate_VB whether_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS
          play_VBP a_DT role_NN in_IN PGIA_NNP ,_, we_PRP performed_VBD adoptive_JJ transfer_NN
          experiments_NNS using_VBG SCID_NNP mice_NNS as_IN recipients_NNS ._. Purified_NNP CD_NNP 4_CD
          +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS (_( 3_CD -_: 20_CD ×_NN 10_CD 5_LS )_) from_IN naïve_NN BALB_NNP /_NN c_SYM
          mice_NNS ,_, together_RB with_IN 10_CD 7_CD spleen_NN cells_NNS from_IN arthritic_JJ mice_NNS
          that_WDT were_VBD depleted_VBN of_IN CD_NNP 25_CD +_NN T_NN cells_NNS and_CC 100_CD μg_NN
          proteoglycan_NN ,_, were_VBD injected_VBN intraperitoneally_RB into_IN SCID_NNP
          mice_NNS [_NN 18_CD ]_NN ,_, and_CC the_DT incidence_NN and_CC severity_NN of_IN disease_NN
          were_VBD monitored_VBN ._. Note_VB that_IN we_PRP used_VBD different_JJ ratios_NNS of_IN the_DT
          CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS to_TO the_DT effector_NN cells_NNS ,_, and_CC
          we_PRP did_VBD not_RB observe_VB any_DT suppression_NN of_IN arthritis_NN
          development_NN ._. As_IN a_DT control_NN ,_, the_DT same_JJ number_NN of_IN CD_NNP 4_CD +_NN CD_NNP 25_CD
          -_: T_NN cells_NNS ,_, together_RB with_IN arthritogenic_JJ spleen_NN cells_NNS that_WDT
          were_VBD depleted_VBN of_IN CD_NNP 25_CD +_NN cells_NNS ,_, and_CC proteoglycan_NN ,_, were_VBD also_RB
          adoptively_RB transferred_VBN into_IN SCID_NNP mice_NNS ._. The_DT transfers_NNS of_IN
          CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS did_VBD not_RB have_VB any_DT impact_NN on_IN incidence_NN
          and_CC severity_NN of_IN the_DT disease_NN in_IN SCID_NNP mice_NNS as_IN compared_VBN with_IN
          transfer_NN of_IN CD_NNP 4_CD +_NN CD_NNP 25_CD -_: T_NN cells_NNS (_( Fig_NNP ._. 3_LS a_DT )_) ,_, suggesting_VBG that_IN
          the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS did_VBD not_RB protect_VB SCID_NNP
          mice_NNS from_IN arthritis_NN ._. To_TO further_VB verify_VB these_DT results_NNS ,_, a_DT
          depletion_NN experiment_NN was_VBD conducted_VBN ._. Spleen_NNP cells_NNS from_IN
          arthritic_JJ animals_NNS ,_, either_CC depleted_VBD of_IN CD_NNP 25_CD +_NN cells_NNS or_CC
          without_IN depletion_NN ,_, were_VBD injected_VBN into_IN SCID_NNP mice_NNS together_RB
          with_IN proteoglycan_NN ._. The_DT incidence_NN and_CC severity_NN of_IN
          arthritis_NN in_IN SCID_NNP mice_NNS receiving_VBG spleen_NN cells_NNS containing_VBG
          CD_NNP 25_CD +_NN cells_NNS or_CC spleen_NN cells_NNS depleted_VBN of_IN CD_NNP 25_CD +_NN cells_NNS were_VBD
          identical_JJ (_( Fig_NNP ._. 3_LS b_SYM )_) ._. Proteoglycan-specific_NNP T-_NNP cell_NN
          proliferation_NN and_CC production_NN of_IN IL-_NNP 4_CD ,_, interferon-γ_JJ ,_,
          IL-_NNP 10_CD ,_, TGF-β_NNP 
          1_CD and_CC antiproteoglycan_NN autoantibodies_NNS
          were_VBD comparable_JJ in_IN both_DT transfer_NN groups_NNS (_( Fig_NNP ._. 3_LS c_SYM )_) ._. The_DT
          inability_NN of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS to_TO
          suppress_VB PGIA_NNP was_VBD not_RB due_JJ to_TO loss_NN of_IN their_PRP$ suppression_NN
          activity_NN ,_, because_IN 
          in_IN vitro_NN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS
          could_MD effectively_RB inhibit_VB the_DT proliferation_NN of_IN the_DT CD_NNP 4_CD
          +_NN CD_NNP 25_CD -_: T_NN cells_NNS (_( Fig_NNP ._. 3_LS d_SYM ,_, left_VBD panel_NN )_) ._. Interestingly_RB ,_,
          proteoglycan-induced_JJ proliferation_NN of_IN CD_NNP 4_CD +_NN CD_NNP 25_CD -_: T_NN cells_NNS
          could_MD not_RB be_VB inhibited_VBD by_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS (_( Fig_NNP ._.
          3_LS d_SYM ,_, right_JJ panel_NN )_) ,_, which_WDT is_VBZ consistent_JJ with_IN a_DT recent_JJ
          report_NN that_IN the_DT effective_JJ function_NN of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD
          +_NN regulatory_JJ T_NN cells_NNS is_VBZ T-_NNP cell_NN receptor_NN (_( TCR_NNP )_) specific_JJ [_NN
          28_CD ]_NN ._. Collectively_RB ,_, our_PRP$ data_NNS suggest_VBP that_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD
          +_NN regulatory_JJ T_NN cells_NNS may_MD not_RB be_VB involved_VBN in_IN the_DT
          development_NN of_IN PGIA_NNP ._.
        
        
          CD_NNP 28_CD -_: deficient_NN mice_NNS have_VBP severely_RB reduced_VBN CD_NNP 4_CD +_NN CD_NNP 25_CD
          +_NN regulatory_JJ T_NN cells_NNS but_CC are_VBP resistant_JJ to_TO PGIA_NNP
          It_PRP has_VBZ been_VBN shown_VBN that_IN CD_NNP 28_CD -_: B_NNP 7_CD interaction_NN is_VBZ
          essential_JJ for_IN the_DT homeostasis_NNS of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD
          +_NN regulatory_JJ T_NN cells_NNS that_WDT control_NN autoimmune_JJ diabetes_NN [_NN 6_CD
          ]_NN ._. Consistent_NNP with_IN that_DT report_NN ,_, the_DT expression_NN of_IN CD_NNP 4_CD
          +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS was_VBD found_VBN to_TO be_VB significantly_RB
          reduced_VBN as_IN compared_VBN with_IN that_DT in_IN wild-type_JJ BALB_NNP /_NN c_SYM mice_NNS
          (_( Fig_NNP ._. 4_LS a_DT )_) ._. To_TO investigate_VB whether_IN a_DT deficiency_NN in_IN the_DT CD_NNP 4_CD
          +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS may_MD lead_VB to_TO an_DT increase_NN in_IN the_DT
          development_NN of_IN PGIA_NNP ,_, we_PRP immunized_JJ wild-type_JJ and_CC
          CD_NNP 28_CD -_: deficient_NN BALB_NNP /_NN c_SYM mice_NNS with_IN proteoglycan_NN ,_, and_CC disease_NN
          incidence_NN was_VBD monitored_VBN ._. In_IN contrast_NN to_TO the_DT report_NN in_IN
          autoimmune_JJ diabetes_NN [_NN 6_CD ]_NN ,_, CD_NNP 28_CD -_: deficient_NN BALB_NNP /_NN c_SYM mice_NNS
          were_VBD highly_RB resistant_JJ to_TO induction_NN of_IN arthritis_NN ,_, albeit_IN
          at_IN a_DT low_JJ percentage_NN of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS
          observed_VBD in_IN these_DT mice_NNS (_( Fig_NNP ._. 4_LS b_SYM )_) ._. Note_VB that_IN T_NN cells_NNS from_IN
          proteoglycan-immunized_JJ CD_NNP 28_CD -_: deficient_NN mice_NNS proliferate_VBP in_IN
          response_NN to_TO proteoglycan_NN stimulation_NN ,_, albeit_IN at_IN a_DT rate_NN
          lower_JJR than_IN that_DT in_IN wild-type_JJ T_NN cells_NNS (_( Fig_NNP ._. 4_LS c_SYM )_) ,_,
          suggesting_VBG that_IN CD_NNP 28_CD -_: deficient_NN T_NN cells_NNS can_MD be_VB effectively_RB
          primed_VBN ._.
        
      
      
        Discussion_NNP
        A_DT controlled_VBN balance_NN between_IN initiation_NN and_CC
        downregulation_NN of_IN immune_JJ responses_NNS (_( peripheral_JJ tolerance_NN )_)
        is_VBZ important_JJ for_IN maintaining_VBG immune_JJ homeostasis_NNS ,_, whereas_IN
        dysfunctional_NN immune_JJ regulation_NN may_MD lead_VB to_TO chronic_JJ
        inflammation_NN or_CC autoimmunity_NN [_NN 29_CD ]_NN ._. The_DT CD_NNP 4_CD +_NN CD_NNP 25_CD
        +_NN regulatory_JJ T_NN cells_NNS have_VBP been_VBN shown_VBN to_TO suppress_VB
        autoimmunity_NN in_IN several_JJ animal_NN models_NNS [_NN 2_CD ]_NN ._. To_TO evaluate_VB
        the_DT role_NN of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS in_IN PGIA_NNP ,_,
        three_CD approaches_NNS were_VBD used_VBN ._. First_LS ,_, the_DT numbers_NNS of_IN the_DT CD_NNP 4_CD
        +_NN CD_NNP 25_CD +_NN cells_NNS in_IN spleens_NNS of_IN susceptible_JJ versus_CC resistant_NN or_CC
        ovalbumin_NN immunized_JJ mice_NNS were_VBD assessed_VBN by_IN flow_NN cytometry_NN at_IN
        day_NN 14_CD following_VBG immunization_NN ._. No_DT significant_JJ change_NN in_IN the_DT
        numbers_NNS of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN cells_NNS was_VBD observed_VBN among_IN
        experimental_JJ groups_NNS tested_VBN (_( Fig_NNP ._. 2_LS a_DT )_) ._. Moreover_RB ,_, the_DT levels_NNS
        of_IN expression_NN of_IN CTLA-_NNP 4_CD in_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN cells_NNS was_VBD similar_JJ
        between_IN groups_NNS ._. These_DT data_NNS suggest_VBP that_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD
        +_NN cells_NNS may_MD not_RB be_VB involved_VBN in_IN the_DT development_NN of_IN PGIA_NNP ._.
        Although_IN the_DT immune_JJ system_NN had_VBD been_VBN perturbed_VBD by_IN
        immunization_NN ,_, CD_NNP 4_CD +_NN T_NN cells_NNS isolated_VBD 14_CD days_NNS after_IN
        immunization_NN of_IN each_DT group_NN did_VBD not_RB show_VB significant_JJ
        increase_NN in_IN CD_NNP 25_CD expression_NN as_IN compared_VBN with_IN that_DT in_IN naïve_NN
        mice_NNS ,_, suggesting_VBG that_IN T_NN cells_NNS activated_VBN by_IN immunization_NN had_VBD
        become_VBN resting_VBG memory_NN T_NN cells_NNS ._.
        To_TO further_VB evaluate_VB the_DT role_NN of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN cells_NNS in_IN
        PGIA_NNP ,_, an_DT adoptive_JJ transfer_NN system_NN was_VBD employed_VBN ._. Different_JJ
        ratios_NNS of_IN activated_VBN effector_NN cells_NNS (_( CD_NNP 25_CD -_: depleted_VBN spleen_NN
        cells_NNS )_) to_TO CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN cells_NNS were_VBD tested_VBN in_IN our_PRP$ cotransfer_NN
        experiments_NNS ._. No_DT suppression_NN of_IN development_NN of_IN PGIA_NNP in_IN SCID_NNP
        mice_NNS was_VBD observed_VBN ._. Although_IN one_PRP could_MD argue_VB that_IN the_DT ratio_NN
        of_IN effector_NN cells_NNS to_TO regulatory_JJ cells_NNS is_VBZ not_RB sufficiently_RB
        great_JJ to_TO inhibit_VB disease_NN ,_, we_PRP tested_VBD a_DT wide_JJ range_NN of_IN ratios_NNS
        of_IN effector_NN cells_NNS to_TO regulatory_JJ cells_NNS (_( 5_CD -_: 30_CD :_: 1_LS )_) in_IN our_PRP$
        transfer_NN system_NN ,_, and_CC similar_JJ results_NNS were_VBD observed_VBN ._. We_PRP did_VBD
        not_RB observe_VB any_DT inhibition_NN at_IN the_DT ratios_NNS used_VBN in_IN the_DT
        present_JJ study_NN ._. However_RB ,_, we_PRP cannot_NN completely_RB exclude_VB the_DT
        possibility_NN that_IN 1_CD -_: 4_CD :_: 1_CD ratios_NNS may_MD be_VB required_VBN for_IN
        suppression_NN of_IN PGIA_NNP ._. In_IN view_NN of_IN the_DT published_VBN literature_NN ,_,
        this_DT is_VBZ unlikely_JJ because_IN most_JJS studies_NNS of_IN this_DT type_NN used_VBD
        ratios_NNS greater_JJR than_IN 20_CD :_: 1_CD [_NN 6_CD ]_NN ._. This_DT finding_VBG is_VBZ further_RBR
        supported_VBN by_IN the_DT evidence_NN that_IN adoptive_JJ transfer_NN of_IN
        CD_NNP 25_CD -_: depleted_VBN splenocytes_NNS from_IN arthritic_JJ mice_NNS does_VBZ not_RB
        exacerbate_VB disease_NN in_IN SCID_NNP mice_NNS ._. The_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS are_VBP
        functionally_RB normal_JJ because_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN cells_NNS can_MD
        significantly_RB inhibit_VB the_DT proliferation_NN of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD
        -_: cells_NNS induced_VBN by_IN TCR_NNP stimulation_NN (_( Fig_NNP ._. 3_LS d_SYM ,_, left_VBD panel_NN )_) ._. No_DT
        alteration_NN in_IN IL-_NNP 10_CD and_CC TGF-β_NNP production_NN could_MD be_VB detected_VBN
        in_IN two_CD transfer_VB groups_NNS (_( Fig_NNP ._. 3_LS c_SYM )_) ._. Taken_VBN together_RB ,_, our_PRP$ data_NNS
        suggest_VBP that_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS may_MD not_RB
        regulate_VB the_DT development_NN of_IN PGIA_NNP ._.
        We_PRP found_VBD that_IN CD_NNP 28_CD -_: deficient_NN mice_NNS ,_, which_WDT have_VBP a_DT low_JJ
        frequency_NN of_IN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN cells_NNS ,_, are_VBP resistant_JJ to_TO PGIA_NNP ._.
        Although_IN one_PRP may_MD argue_VB that_IN ,_, in_IN the_DT absence_NN of_IN CD_NNP 28_CD ,_, T-_NNP cell_NN
        priming_VBG by_IN proteoglycan_NN immunization_NN may_MD be_VB defective_JJ ._.
        However_RB ,_, CD_NNP 28_CD -_: deficient_NN T_NN cells_NNS from_IN proteoglycan-immunized_JJ
        animals_NNS can_MD proliferate_VBP in_IN response_NN to_TO proteoglycan_NN
        stimulation_NN 
        in_IN vitro_NN ,_, albeit_IN at_IN a_DT rate_NN lower_JJR
        than_IN that_DT in_IN wild-type_JJ T_NN cells_NNS ,_, which_WDT is_VBZ consistent_JJ with_IN
        the_DT report_NN by_IN Oliveira-dos-_NNP Santos_NNP 
        et_CC al_NN ._. [_NN 30_CD ]_NN ._. It_PRP has_VBZ been_VBN
        demonstrated_VBN that_IN ,_, in_IN the_DT absence_NN of_IN CD_NNP 28_CD engagement_NN ,_, T_NN
        cells_NNS require_VBP very_RB high_JJ TCR_NNP occupancy_NN and_CC prolonged_JJ
        stimulation_NN ,_, whereas_IN CD_NNP 28_CD costimulation_NN allows_VBZ T_NN cells_NNS to_TO
        respond_VB to_TO lower_JJR degrees_NNS of_IN TCR_NNP occupancy_NN [_NN 30_CD 31_CD ]_NN ._. In_IN
        support_NN of_IN this_DT observation_NN ,_, CD_NNP 28_CD -_: /_NN -_: mice_NNS can_MD still_RB mount_VB
        immune_JJ responses_NNS ,_, which_WDT vary_VBP in_IN magnitude_NN and_CC efficiency_NN
        depending_VBG on_IN the_DT antigen_NN or_CC infectious_JJ agent_NN [_NN 30_CD 32_CD ]_NN ._.
        Our_PRP$ results_NNS and_CC those_DT reported_VBN by_IN others_NNS [_NN 30_CD ]_NN suggest_VBP
        that_IN CD_NNP 28_CD may_MD regulate_VB the_DT threshold_NN for_IN T-_NNP cell_NN activation_NN ._.
        In_IN support_NN of_IN this_DT notion_NN ,_, immunization_NN of_IN CD_NNP 28_CD -_: deficient_NN
        mice_NNS with_IN high_JJ concentrations_NNS of_IN myelin_NN basic_JJ protein_NN
        induces_VBZ experimental_JJ autoimmune_JJ encephalomyelitis_NNS at_IN
        similar_JJ prevalence_NN and_CC severity_NN as_IN in_IN wild-type_JJ mice_NNS [_NN 30_CD ]_NN
        ._. Our_PRP$ data_NNS suggest_VBP that_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS
        might_MD be_VB important_JJ for_IN controlling_VBG spontaneous_JJ models_NNS of_IN
        autoimmunity_NN but_CC not_RB for_IN induced_VBN models_NNS of_IN autoimmunity_NN ._. In_IN
        induced_VBN models_NNS of_IN autoimmunity_NN ,_, the_DT CD_NNP 28_CD -_: B_NNP 7_CD interaction_NN has_VBZ
        been_VBN shown_VBN to_TO regulate_VB disease_NN susceptibility_NN by_IN rendering_VBG
        autoreactive_JJ T_NN cells_NNS anergic_JJ ,_, or_CC alternatively_RB by_IN
        upregulating_VBG the_DT threshold_NN for_IN autoreactive_JJ T-_NNP cell_NN
        activation_NN [_NN 30_CD ]_NN ._. Furthermore_RB ,_, we_PRP previously_RB showed_VBD that_WDT
        impaired_VBN Fas-mediated_NNP activation-induced_JJ cell_NN death_NN (_( AICD_NNP )_)
        of_IN autoreactive_JJ T-_NNP helper-_NN 1_CD cells_NNS may_MD be_VB responsible_JJ for_IN the_DT
        development_NN of_IN PGIA_NNP [_NN 20_CD ]_NN ._. Therefore_RB ,_, AICD_NNP and_CC /_NN or_CC T-_NNP cell_NN
        anergy_NN ,_, but_CC not_RB the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS ,_, may_MD be_VB
        responsible_JJ for_IN deletion_NN or_CC inactivation_NN of_IN autoreactive_JJ T_NN
        cells_NNS in_IN autoimmune_JJ arthritis_NN ._.
      
      
        Conclusion_NNP
        Our_PRP$ results_NNS showed_VBD that_IN the_DT percentage_NN of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD
        +_NN regulatory_JJ T_NN cells_NNS does_VBZ not_RB change_VB during_IN the_DT development_NN
        of_IN PGIA_NNP ._. The_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS do_VBP not_RB protect_VB
        SCID_NNP mice_NNS from_IN arthritis_NN when_WRB they_PRP are_VBP cotransferred_JJ with_IN
        spleen_NN cells_NNS from_IN arthritic_JJ mice_NNS and_CC proteoglycan_NN into_IN SCID_NNP
        mice_NNS ._. Transfer_NN of_IN spleen_NN cells_NNS from_IN arthritic_JJ mice_NNS ,_,
        depleted_VBN of_IN the_DT CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS ,_, into_IN SCID_NNP
        mice_NNS does_VBZ not_RB accelerate_VB the_DT disease_NN ._. Furthermore_RB ,_,
        CD_NNP 28_CD -_: deficient_NN mice_NNS ,_, which_WDT are_VBP deficient_NN for_IN CD_NNP 4_CD +_NN CD_NNP 25_CD +_NN T_NN
        cells_NNS ,_, are_VBP resistant_JJ to_TO PGIA_NNP ._. Our_PRP$ data_NNS suggest_VBP that_IN the_DT CD_NNP 4_CD
        +_NN CD_NNP 25_CD +_NN regulatory_JJ T_NN cells_NNS may_MD not_RB be_VB essential_JJ for_IN
        controlling_VBG experimentally_RB induced_VBN autoimmune_JJ
        arthritis_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        AICD_NNP =_SYM activation-induced_JJ cell_NN death_NN ;_: CTLA_NNP =_SYM cytotoxic_JJ
        T-_NNP lymphocyte_NN antigen_NN ;_: ELISA_NNP =_SYM enzyme-linked_JJ immunosorbent_NN
        assay_NN ;_: FITC_NNP =_SYM fluorescein_NN isothiocyanate_NN ;_: IL_NNP =_SYM interleukin_NN ;_:
        PE_NNP =_SYM R-_NNP phycoerythrin_NN ;_: PG_NNP =_SYM proteoglycan_NN ;_: PGIA_NNP ,_,
        proteoglycan-induced_JJ arthritis_NN ;_: SCID_NNP =_SYM severe_JJ combined_VBN
        immunodeficient_NN ;_: TCR_NNP =_SYM T-_NNP cell_NN receptor_NN ;_: TGF_NNP =_SYM transforming_VBG
        growth_NN factor_NN ;_: WT_NNP =_SYM wild-type_JJ ._.
      
    
  
